Brokers Offer Predictions for NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Brookline Capital Acquisition decreased their FY2026 EPS estimates for Intellia Therapeutics in a research note issued on Thursday, February 26th. Brookline Capital Acquisition analyst L. Cann now anticipates that the company will post earnings per share of ($3.11) for the year, down from their prior forecast of ($2.13). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Acquisition also issued estimates for Intellia Therapeutics’ FY2027 earnings at $15.05 EPS and FY2030 earnings at $78.43 EPS.

Several other research firms have also commented on NTLA. Wolfe Research restated a “peer perform” rating on shares of Intellia Therapeutics in a research report on Wednesday, November 12th. Wall Street Zen cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 18th. Wells Fargo & Company cut their price target on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. JonesTrading lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, KeyCorp set a $25.00 target price on Intellia Therapeutics in a research report on Wednesday, January 28th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $17.90.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $13.78 on Monday. The firm has a market capitalization of $1.63 billion, a PE ratio of -3.60 and a beta of 2.09. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The business’s fifty day moving average price is $11.89 and its two-hundred day moving average price is $13.05.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The business had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. During the same period in the prior year, the firm earned ($1.27) EPS. The business’s quarterly revenue was up 78.4% on a year-over-year basis.

Institutional Investors Weigh In On Intellia Therapeutics

A number of large investors have recently made changes to their positions in the company. ARK Investment Management LLC lifted its position in shares of Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after acquiring an additional 2,288,146 shares in the last quarter. Vanguard Group Inc. raised its stake in Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after purchasing an additional 1,965,181 shares during the period. State Street Corp raised its stake in Intellia Therapeutics by 29.1% during the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after purchasing an additional 1,447,967 shares during the period. Contrarius Group Holdings Ltd lifted its holdings in shares of Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after purchasing an additional 4,337,428 shares in the last quarter. Finally, Baker BROS. Advisors LP boosted its position in shares of Intellia Therapeutics by 2.7% in the third quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock worth $47,435,000 after buying an additional 71,000 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP James Basta sold 10,397 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the sale, the executive vice president owned 101,528 shares in the company, valued at approximately $935,072.88. The trade was a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is owned by insiders.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations: Intellia reported a smaller-than-expected loss (‑$0.83 vs. consensus ‑$0.99) and revenue of $23.0M (well above estimates), which investors view as proof of commercial progress and operational execution. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Positive Sentiment: Pipeline and regulatory progress: FDA lifted the clinical hold on MAGNITUDE‑2 (nex‑z) and management outlined 2026 launch plans for lonvo‑z (HAE) with mid‑2026 Phase 3 readout expectations and a potential BLA in H2 2026 — milestones that materially de‑risk commercial timelines if achieved. Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Strong cash runway: Intellia ended 2025 with roughly $605M in cash, cash equivalents and marketable securities — a balance that supports continued clinical development and commercial preparation into the near‑term. Intellia Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” and set a $26 price target, signaling notable upside from current levels and providing dealer/retail validation for the bull case. Benzinga
• Neutral Sentiment: Broker estimates: Brookline Capital published a slate of near‑term quarterly EPS forecasts (all negative) but raised long‑range FY2028/FY2029 EPS projections, reflecting high uncertainty today but improved long‑term expectations if pipeline succeeds. MarketBeat Q4 coverage / analyst notes
• Neutral Sentiment: Earnings call detail: Management emphasized commercial readiness for lonvo‑z and clinical plans for nex‑z; transcripts and call highlights are available for deeper review. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Profitability and consensus outlook remain weak: the company still posts large negative margins and the consensus full‑year EPS forecast is deeply negative, keeping NTLA a high‑volatility, binary biotech bet until clinical/commercial milestones are met. MarketBeat: Q4 results and metrics
• Negative Sentiment: Market reaction: despite the positive operational news, the shares are trading lower today — likely reflecting profit‑taking, macro/sector pressure on biotech, and investor caution about execution risk and near‑term losses.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.